Protection Against Chemotherapy-Induced Alopecia

Wang, Jie; Lu, Ze; Au, Jessie L.-S.

doi:10.1007/s11095-006-9105-3

Cited by 114 publications

(143 citation statements)

References 94 publications

(58 reference statements)

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…Among the many pharmacological approaches for alopecia prevention that were investigated, vitamin D 3 appeared to be the most promising protective compound because it was effective against several different antineoplastic agents in preclinical experiments (e.g., Jimenez et al 1995;Schilli et al 1998). However, a clinical trial was ultimately unsuccessful (Hidalgo et al 1999;Wang et al 2006).…”

mentioning

confidence: 99%

Prevention of chemotherapy-induced alopecia in rodent models

Jiménez

Roberts

Mejia

et al. 2008

Cell Stress and Chaperones

View full text Add to dashboard Cite

Alopecia (hair loss) is experienced by thousands of cancer patients every year. Substantial-to-severe alopecia is induced by anthracyclines (e.g., adriamycin), taxanes (e.g., taxol), alkylating compounds (e.g., cyclophosphamide), and the topisomerase inhibitor etoposide, agents that are widely used in the treatment of leukemias and breast, lung, ovarian, and bladder cancers. Currently, no treatment appears to be generally effective in reliably preventing this secondary effect of chemotherapy. We observed in experiments using different rodent models that localized administration of heat or subcutaneous/intradermal injection of geldanamycin or 17-(allylamino)-17-demethoxygeldanamycin induced a stress protein response in hair follicles and effectively prevented alopecia from adriamycin, cyclophosphamide, taxol, and etoposide. Model tumor therapy experiments support the presumption that such localized hair-saving treatment does not negatively affect chemotherapy efficacy.

show abstract

mentioning

confidence: 99%

Prevention of chemotherapy-induced alopecia in rodent models

Jiménez

Roberts

Mejia

et al. 2008

Cell Stress and Chaperones

View full text Add to dashboard Cite

show abstract

“…Multiple improvements in the treatment of the other side effects of chemotherapy have been developed and introduced successfully, while the development of CIA treatments has been lagging behind with no available effective therapy. 19 Wang et al 19 nicely reviewed the different aspects of this problem. There are no approved preventative treatments for CIA in humans although several experimental and pharmacological approaches are under evaluation.…”

Section: Discussionmentioning

confidence: 99%

“…Treatments to prevent or minimize alopecia include physical means such as scalp tourniquets (no longer used due to patient discomfort) 20 and scalp hypothermia, 11,21 and pharmacologic means that include topical vitamin D 3 analogue, 22 AS101, 23 Minoxidil [24][25][26] or Cs 27,28 and other experimental drugs. 19 Most of these treatments have either limited or very selective activity or have not been tested in humans yet.…”

Section: Discussionmentioning

confidence: 99%

Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation

Machado

Moreb

Khan

2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Alopecia, a side effect of chemotherapy, is usually temporary and reversible. Irreversible alopecia has been reported after high-dose chemotherapy (HDC) and hematopoietic stem cell transplantation (HSCT) especially related to BuCy containing conditioning regimens; however, the overall incidence is not known. We conducted a retrospective study to identify patients with chemotherapy-induced permanent alopecia after HSCT. We describe six such patients, two males and four females, among 760 patients transplanted between 1997 and 2004. Median age was 45 years (range, 37-65). There were three Caucasians and three African-Americans. Median follow-up was 30 months. Conditioning regimens included BuCy, Bu/Cy and etoposide (VP16) (one of these patients received second autograft after Cy and TBI) and CyVP16 and TBI. Our data show that permanent alopecia is a significant long-term side effect of HSCT and can be seen across the spectrum of diseases and transplant types and with non-busulfan containing regimens. We have observed that patients usually accept permanent alopecia as the price for the cure and therefore true incidence of permanent alopecia may be underestimated. Our findings may also have medico legal and psychosocial implications that need to be taken into consideration when consenting patients for HSCT.

show abstract

“…77 Specifically, Zinc may influence hair biology via its immunomodulatory effects. 77,78 Its antioxidant effects may stem from indirect stimulation of certain endogenous chemicals into metallothionein which possess superior antioxidant activities.…”

Section: Zincmentioning

confidence: 99%

Addressing Androgenetic Alopecia-A Complex Disorder-with a Multilateral Treatment Strategy

Patel¹

2017

MOJBB

View full text Add to dashboard Cite

Protection Against Chemotherapy-Induced Alopecia

Cited by 114 publications

References 94 publications

Prevention of chemotherapy-induced alopecia in rodent models

Prevention of chemotherapy-induced alopecia in rodent models

Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation

Addressing Androgenetic Alopecia-A Complex Disorder-with a Multilateral Treatment Strategy

Contact Info

Product

Resources

About